Processa Pharmaceuticals, Inc. Common (PCSA)
Processa Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing pharmaceutical products for serious and unmet medical conditions. The company emphasizes innovative drug development, often targeting niche markets with unmet needs, leveraging its expertise in formulation and clinical development processes.
Company News
Processa Pharmaceuticals saw a significant stock price increase after initiating a Phase 2 clinical trial for next-generation capecitabine (NGC-Cap) as a potential treatment for advanced breast cancer, with interim results expected in mid-2025.
Processa Pharmaceuticals announced the acceptance of three abstracts for the 2025 ASCO Annual Meeting, highlighting its pipeline of Next Generation Cancer (NGC) drug candidates, including PCS6422 (NGC-Cap) and PCS11T (NGC-Iri).
Here's how to spot penny stocks with potential uptrends The post Spotting Penny Stocks Uptrends, 3 Top Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Heatwurx Inc. (PCSA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.